uniQure N.V.

NASDAQ:QURE

Biotechnology

Healthcare
$20.30 -2.34%

-$1.13 today

Market cap
$1.42B
Beta
1.00
P/E (TTM)
-14.1
EPS (TTM)
-$3.33
52W Low $8.73High $71.50

Volume 1.13M

Average 1.75M

QURE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

uniQure N.V.NASDAQ: QURE

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $29.18M fell 19.3% year over year, behind the -4.7% change in trailing-twelve-month research & development. Sequentially, it fell 13.8% from the prior quarter. Over 3 fiscal years it compounded at -10.7% a year.

Context

  • Research & development amounted to 873.9% of revenue in FY2025, up 343.7 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -19.3% toward the trailing-twelve-month pace of -4.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$29.18M-13.8% QoQ
Last fiscal yearDec 2025
$140.67M-2.2% YoY
LTMMar 2026
$132.76M-4.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.3%——
1 year-2.2%——
3-year CAGR-10.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
140.67M USD
Year-over-year change
-2.2%
4-year CAGR
-0.5%

Research & Development vs competitors

How QURE compares with its peers on the latest reported figures

  • QURE's LTM Mar 2026 research & development of $132.76M is the 5th highest of the 8 companies compared; the peer median is $137.53M.
  • Its year-over-year change of -4.7% is the 7th highest of 8, against a peer median of +12.5%.
  • Research & development amounts to 733.7% of revenue for QURE, versus a peer median of 249.3%.
QURE Competitors Peer median
Research & Development for QURE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$770.95M +12.5%+2.0%115.2%
RGNXREGENXBIO Inc.LTM Mar 2026$228.65M +12.8%-2.0%260.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$219.98M +42.7%+34.6%249.3%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$137.53M -14.3%-5.0%—
QUREuniQure N.V.LTM Mar 2026$132.76M -4.7%-10.7%733.7%
MGTXMeiraGTx Holdings plcLTM Mar 2026$128.82M +9.2%+14.8%161.5%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$127.75M -3.1%+30.4%350.1%
NGNENeurogene Inc.LTM Mar 2026$82.4M +26.5%+16.4%—
Peer median (excluding QURE) $137.53M+12.5%+14.8%249.3%

Competitors are the stored peer set for QURE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue524M106.48M15.84M27.12M16.1M
Cost of Revenue24.98M3.34M13.63M18.33M1.69M
Gross Profit499.03M103.14M2.22M8.79M14.41M
Gross Margin95.2%96.9%14.0%32.4%89.5%
Research & Development143.55M197.59M214.86M143.78M140.67M
Selling, General & Admin56.29M54.7M73.08M50.68M65.34M
Operating Expenses188.41M246.3M285.09M193.09M202.24M
Depreciation & Amortization7.3M8.54M11.9M12.64M14.76M
EBITDA319M(108.02M)(253.1M)(160.75M)(116.59M)
EBITDA Margin60.9%-101.4%-1597.6%-592.7%-724.2%
Operating Income310.62M(143.16M)(282.87M)(184.29M)(187.83M)
Operating Margin59.3%-134.4%-1785.5%-679.6%-1166.8%
Interest Income162K609K19.56M21.42M16.97M
Interest Expense7.47M11.7M41.56M63.74M61.99M
Other Income / Expenses22.19M14.9M(23.69M)(52.83M)(5.51M)
Income Before Tax332.81M(128.26M)(306.56M)(237.13M)(193.34M)
Pre-Tax Margin63.5%-120.5%-1935.0%-874.4%-1201.0%
Income Tax Expense3.22M(1.47M)1.92M2.43M5.63M
Net Income329.59M(126.79M)(308.48M)(239.56M)(198.97M)
Net Margin62.9%-119.1%-1947.1%-883.4%-1236.0%
EPS (Basic)7.17(2.71)(6.47)(4.92)(3.46)
EPS (Diluted)7.04(2.71)(6.47)(4.92)(3.46)
Weighted Avg Shares45.99M46.74M47.67M48.65M57.5M
Weighted Avg Shares (Diluted)46.84M46.74M47.67M48.65M57.5M

uniQure N.V.

NASDAQ:QURE

Intrinsic Alpha fair value

Locked

Current Price

$20.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.